ABCB1 (P-glycoprotein) reduces bacterial attachment to human gastrointestinal LS174T epithelial cells.

[1]  A. Crowe.  The role of P-glycoprotein and breast cancer resistance protein (BCRP) in bacterial attachment to human gastrointestinal cells. , 2011, Journal of Crohn's & colitis.

[2]  K. Ahrens,et al.  Differential suppression of epidermal antimicrobial protein expression in atopic dermatitis and in EFAD mice by pimecrolimus compared to corticosteroids , 2011, Experimental dermatology.

[3]  Linhao Li,et al.  A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. , 2010, Biochemical pharmacology.

[4]  B. P. Kota,et al.  Characterization of PXR mediated P-glycoprotein regulation in intestinal LS174T cells. , 2010, Pharmacological research.

[5]  A. Crowe,et al.  Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. , 2010, Journal of pharmacological sciences.

[6]  S. Schreiber,et al.  Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. , 2009, Pharmacogenomics.

[7]  M. Pazgier,et al.  Through the Looking Glass, Mechanistic Insights from Enantiomeric Human Defensins* , 2009, The Journal of Biological Chemistry.

[8]  Y. Takeda,et al.  Bacterial exotoxins downregulate cathelicidin (hCAP‐18/LL‐37) and human β‐defensin 1 (HBD‐1) expression in the intestinal epithelial cells , 2008, Cellular microbiology.

[9]  Guangshun Wang,et al.  Structures of Human Host Defense Cathelicidin LL-37 and Its Smallest Antimicrobial Peptide KR-12 in Lipid Micelles* , 2008, Journal of Biological Chemistry.

[10]  A. Crowe,et al.  pH dependent efflux of methamphetamine derivatives and their reversal through human Caco-2 cell monolayers. , 2008, European journal of pharmacology.

[11]  Uwe Muenster,et al.  Characterization of Substrates and Inhibitors for the In Vitro Assessment of Bcrp Mediated Drug–Drug Interactions , 2008, Pharmaceutical Research.

[12]  B. McCormick,et al.  Salmonella enterica serovar Typhimurium modulates P-glycoprotein in the intestinal epithelium. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[13]  S. Goel,et al.  Bacterial survival and regrowth in drinking water systems. , 2008, Journal of environmental science & engineering.

[14]  T. Davis,et al.  Role of P Glycoprotein in Absorption of Novel Antimalarial Drugs , 2006, Antimicrobial Agents and Chemotherapy.

[15]  Christopher J Endres,et al.  The role of transporters in drug interactions. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  S. Teng,et al.  THE ROLE OF PREGNANE X RECEPTOR IN 2-ACETYLAMINOFLUORENE-MEDIATED INDUCTION OF DRUG TRANSPORT AND -METABOLIZING ENZYMES IN MICE , 2006, Drug Metabolism and Disposition.

[17]  K. H. Banner,et al.  Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene , 2004, British journal of pharmacology.

[18]  K. Brouwer,et al.  Effect of GF120918, a Potent P-glycoprotein Inhibitor, on Morphine Pharmacokinetics and Pharmacodynamics in the Rat , 1998, Pharmaceutical Research.

[19]  James M. Wilson,et al.  Cathelicidins - a family of multifunctional antimicrobial peptides , 2003, Cellular and Molecular Life Sciences CMLS.

[20]  C. Beglinger,et al.  Gene expression of CYP3A4, ABC‐transporters (MDR1 and MRP1‐MRP5) and hPXR in three different human colon carcinoma cell lines , 2003, The Journal of pharmacy and pharmacology.

[21]  D. Rigal,et al.  Transcriptional regulators of the human multidrug resistance 1 gene: recent views. , 2002, Biochemical pharmacology.

[22]  G. Reid,et al.  Can bacterial interference prevent infection? , 2001, Trends in microbiology.

[23]  A. Servin,et al.  Escherichia coli strains colonising the gastrointestinal tract protect germfree mice againstSalmonella typhimuriuminfection , 2001, Gut.

[24]  A. Seelig,et al.  Structure-activity relationship of P-glycoprotein substrates and modifiers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[25]  M. Kagnoff,et al.  Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. , 1999, Journal of immunology.

[26]  D. Ross,et al.  Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp). , 1999, Anticancer research.

[27]  J. C. Jones,et al.  References Subscriptions Permissions Email Alerts A Novel Model of Inflammatory Bowel Disease: Mice Deficient for the Multiple Drug Resistance Gene, mdr1a, Spontaneously Develop Colitis , 2013 .

[28]  P. Borst,et al.  Availability of PSC833, a Substrate and Inhibitor of P-glycoproteins, in Various Concentrations of Serum , 1998 .

[29]  P. Panigrahi,et al.  Escherichia coli Transcytosis in a Caco-2 Cell Model: Implications in Neonatal Necrotizing Enterocolitis1 , 1996, Pediatric Research.

[30]  A. L. Koch,et al.  Turbidity measurements of bacterial cultures in some available commercial instruments. , 1970, Analytical biochemistry.